{"id":"adriamycin-cyclophosphamide-vindesine-valproic-acid","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"5-20%","effect":"Cardiotoxicity"},{"rate":"5-15%","effect":"Neuropathy"}]},"_chembl":{"chemblId":"CHEMBL109","moleculeType":"Small molecule","molecularWeight":"144.21"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Adriamycin's mechanism involves the formation of free radicals that damage DNA, leading to cell death. Cyclophosphamide's mechanism involves the formation of DNA cross-links that prevent DNA replication and transcription. Vindesine's mechanism involves the disruption of microtubule formation, which is essential for cell division. Valproic acid's mechanism involves the inhibition of histone deacetylases, which leads to the modulation of gene expression and the induction of apoptosis.","oneSentence":"Adriamycin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II, and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Vindesine is a vinca alkaloid that binds to tubulin, disrupting microtubule formation and cell division. Valproic acid is a histone deacetylase inhibitor that modulates gene expression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:51.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer, Metastatic ovarian cancer, Metastatic non-small cell lung cancer"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT00759824","phase":"PHASE2","title":"A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide","status":"COMPLETED","sponsor":"European Lung Cancer Working Party","startDate":"2008-09","conditions":"Small Cell Lung Carcinoma","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Adriamycin, cyclophosphamide, vindesine, valproic acid","genericName":"Adriamycin, cyclophosphamide, vindesine, valproic acid","companyName":"European Lung Cancer Working Party","companyId":"european-lung-cancer-working-party","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adriamycin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II, and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Vindesine is a vinca alkaloid that binds to tubulin, disrupting microtubule formation and cell division. Valproic acid is a histone deacetylase inhibitor that modulates gene expression. Used for Metastatic breast cancer, Metastatic ovarian cancer, Metastatic non-small cell lung cancer, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}